Personalizing Multiple Myeloma Prognosis and Treatment: Advanced Single-Cell Genomics Analysis of the Dynamics of Tumor-Immune Crosstalk
Grant Amount: NIS 4.2 Million
About the Project
Multiple myeloma is the second most prevalent blood cancer worldwide, which, despite tremendous improvement in treatment, remains incurable. The research study will provide clinicians with new and powerful molecular tools for early disease detection, predicting treatment response, and for developing novel treatments for multiple myeloma.
Research Team
Prof. Ido Amit
Weizmann Institute of Science (Immunology)
Dr. Moshe Gatt
Hadassah Hebrew University Medical Center (Hematology) 
Dr. Chamutal Gur
Hadassah Medical Center, Ein Kerem (Department of Medicine)
Dr. Yael Cohen
Tel-Aviv Sourasky Medical Center (Hematology) and Tel-Aviv University (Sackler Faculty of Medicine)
More Projects Funded